Serum Antibodies to the Deleted Dystrophin Sequence after Cardiac Transplantation in a Patient with Becker's Muscular Dystrophy

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice

“…30,31 This was also described for humans. 13,48 Production of a low level of Ab cannot be excluded if revertants appear late in development. This response could be further boosted by injecting a dystrophin vector.…”

Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy

“…These experiments demonstrate the potential risk of deleterious effects following gene therapy in DMD patients and lead us to suggest that patients enrolled in gene therapy trials should ideally have small, preferably point, mutations and evidence of 'revertant' dystrophin-positive muscle fibres. Gene Therapy (2000) 7, 1439-1446. ferred dystrophin is suggested by the presence of antibodies specific to the donor dystrophin after cardiac transplantation in a patient with BMD 10 and DMD patients receiving donor myoblast transplantation. 11,12 Similarly, anti-dystrophin antibodies have been noted in animal studies following congenic normal myoblast transplantation into dystrophic mice 13,14 or in vivo gene delivery using recombinant adenoviruses.…”

High affinity anti‐BSEP antibodies after liver transplantation for PFIC‐2 – Successful treatment with immunoadsorption and B‐cell depletion

“…Antibody formation against a specific protein, formerly unknown to the host's immune system, has been described in a patient with Becker's muscular dystrophy after heart transplantation . In this case, antibodies directed against the deleted part of dystrophin could be detected; however, their functional relevance remained uncertain .…”

“…Antibody formation against a specific protein, formerly unknown to the host's immune system, has been described in a patient with Becker's muscular dystrophy after heart transplantation . In this case, antibodies directed against the deleted part of dystrophin could be detected; however, their functional relevance remained uncertain . In patients with Alport syndrome, frequently due to mutations in type IV collagen α5 chain, anti‐GBM nephritis develops in 3–5% after kidney transplantation, caused by anti‐GBM antibodies directed against the carboxy‐terminal non‐collagenous domain of the mutated chain .…”